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BACKGROUND: Steatosis is currently the most common chronic liver disease and it can aggravate ischemia-reperfusion (IR) 
lesions. We hypothesized that S-nitroso-N-acetylcysteine (SNAC), an NO donor component, can ameliorate cell damage from IR 
injury. In this paper, we report the effect of SNAC on liver IR in rats with normal livers compared to those with steatotic livers. 
METHODS: Thirty-four rats were divided into five groups: I (n=8), IR in normal liver; II (n=8), IR in normal liver with SNAC; 
III (n=9), IR in steatotic liver; IV (n=9), IR in steatotic liver with SNAC; and V (n=10), SHAN. Liver steatosis was achieved by 
administration of a protein-free diet. A SNAC solution was infused intraperitoneally for one hour, beginning 30 min. after partial 
(70%) liver ischemia. The volume of solution infused was 1 ml/100 g body weight. The animals were sacrificed four hours after 
reperfusion, and the liver and lung were removed for analysis. We assessed hepatic histology, mitochondrial respiration, oxidative 
stress (MDA), and pulmonary myeloperoxidase. 
RESULTS: All groups showed significant alterations compared with the group that received SHAN. The results from the steatotic 
SNAC group revealed a significant improvement in liver mitochondrial respiration and oxidative stress compared to the steatotic 
group without SNAC. No difference in myeloperoxidase was observed. Histological analysis revealed no difference between the 
non-steatotic groups. However, the SNAC groups showed less intraparenchymal hemorrhage than groups without SNAC (p=0.02). 
CONCLUSION: This study suggests that SNAC effectively protects against IR injury in the steatotic liver but not in the normal liver. 
KEYWORDS: Fatty liver, S-nitrosothiol, S-nitroso-N-acetylcysteine, reperfusion injury, oxidative stress. 
INTRODUCTION
In the last thirty years, hepatic steatosis has been well-
documented as the most common chronic liver disease in the 
general population. Its high prevalence is of epidemiological 
concern because it affects 31% of adults as evaluated by 
magnetic resonance imaging in the USA1 and 33% of 
living donor candidates who underwent liver biopsy.2 The 
prevalence is directly related to age and varies from 2.6% in 
children to 26% in adults who are 40 to 59 years old.3 
The pathophysiology of steatosis has not been 
completely ascertained. The condition may be a consequence 
of mitochondrial β-oxidation impairment, leading to 
increased free fatty acids inside the hepatocyte;4 or it 
may be the cause of oxidative dysfunction, thus leading 
to structural and functional mitochondrial changes.5 
Liver inflammation can also be a trigger of steatosis. 
Either as isolated or cooperative factors, mitochondrial 
dysfunction, inflammatory cytokines, free fatty acids, 
bacterial endotoxins, microvascular injury, and oxidative 
stress may all be involved in the pathogenesis of ischemia-
reperfusion (IR) injury.6-8
Previous studies have demonstrated that steatosis can 
worsen the effect of IR lesions in liver transplantation and 
hepatectomy.9-12 These two factors, steatosis and IR lesions, 
are important because of the high prevalence of steatosis 
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in the general population and the common risk of IR 
injury in liver transplantation and other hepatic surgeries. 
Microvascular alterations, mitochondrial dysfunction, 
and a lower number of sinusoids in steatosis are factors 
that worsen the effect of IR injury in steatotic livers.7,13,14 
Moreover, fatty free acids inhibit acetyl coenzyme A, an 
important factor in the Krebs cycle and gluconeogenesis, 
thus leading to decreased production of ATP.14,15 
Therefore, oxidative stress and hepatic microcirculatory 
damage are related to steatosis and the genesis of IR 
lesions.13,14,16,17 Nitric oxide (NO) has conflicting effects on 
IR; it can improve hepatic microcirculation at low doses.5,18-22 
S-nitroso-N-acetylcysteine (SNAC) is an S-nitrosothiol 
that can act as an NO carrier and donor. NO has a systemic 
and tissue vasodilatation effect and also acts in hepatic 
microcirculation.23 It is suggested that NO could ameliorate 
hepatic microcirculation, which is a pathophysiological 
factor in steatotic liver IR injury.
SNAC amelioration of oxidative stress in experimental 
models of steatosis24 and IR injury of skeletal muscle25 can 
also revert and inhibit the development of non alcoholic fat 
liver disease (NAFLD).39,26 Although it has been studied in 
steatosis and IR injury of skeletal muscle, SNAC has not 
been studied in hepatic IR models or in steatotic liver IR 
models. In this study, we assessed the effect of SNAC in rats 




Thirty-five adult male Wistar rats that weighed 250 to 
300 g were used for this study. All rats were maintained 
in a daily 12 h light-dark cycle. The rats were randomly 
distributed into five groups. Rats in group I (n=8) did not 
have steatosis (received a balanced diet) and were treated 
with saline solution. Rats in group II (n=8) did not have 
steatosis and were treated with SNAC. Rats in group III 
(n=9) had steatosis (received a protein-free diet) and were 
treated with saline solution. Rats in group IV (n=9) had 
steatosis and were treated with SNAC. Rats in group V 
(n=9) comprised the SHAN group; the same surgery was 
performed but without IR injury. A protein-free diet 27 was 
fed to rats for 21 days to induce steatosis. The control group 
was fed a balanced diet (Nuvilab) for the same period. After 
21 days of treatment, the animals underwent IR injury.
The animals were handled under protocols approved 
by the Ethics Committee of the Clinical Hospital of Sao 
Paulo University in Brazil. The Guide for the Care and 
Use of Laboratory Animals (Institute of Laboratory Animal 
Resources, Commission on Life Sciences and National 
Research Council. National Academy Press, Washington, 
D.C., 1996) was used to ensure proper care and protection 
of the experimental animals. 
SNAC preparation
N-acetylcysteine (NAC) and sodium nitrite (Sigma, 
St. Louis, MO, USA) were used for SNAC preparation. 
Aqueous SNAC stock solution was prepared by combining 
an equimolar NAC solution with sodium nitrite. The final 
solution was stirred at room temperature for 20 min and was 
protected from light with aluminum foil. The SNAC solution 
was diluted in saline solution to a final concentration of 100 
nM and used immediately.
Induction of liver IR injury
The rats were anesthetized with intraperitoneal ketamine 
hydrochloride 5% (Park-Davis Lab, USA) and chloridrate of 
xylazine 2% (Rompum®, Bayer) at a dose of 30 mg/kg. Rats 
then underwent endotracheal intubation and were maintained 
at a rectal temperature of 35 to 37°C. A median laparotomy 
was performed, the ligaments of the liver were cut, all 
structures in the portal triad (hepatic artery, portal vein, and 
bile duct) of the median and left lateral hepatic lobes (70% 
of the liver) were clamped with an atraumatic microvascular 
clamp for 1 h (Figure 1), and the abdomen was closed. 
Then a second laparotomy was performed, the clamp was 
removed, and the animals were kept alive for 4 h after 
reperfusion. The SNAC solution (100 nM) was administrated 
intraperitonealy (i.p.) at a dose of 1 ml/100 g body weight 
for 1 h, starting 30 min after occlusion of the blood supply 
to the median and left hepatic lobes. Fifteen min before 
Figure 1 - Structures in the portal triad (hepatic artery, portal vein, and bile 
duct) in the median and left lateral hepatic lobes (70% of the liver) clamped 
with an atraumatic, microvascular clamp.
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euthanasia by exsanguination, Evans blue (Sigma-Chemical 
Company, USA) was injected intravenously. The liver was 
removed, and both ischemic and non-ischemic portions 
were evaluated for histology, lipid peroxidation (MDA) and 
mitochondrial function. The lung was removed for Evans 
blue extraction and myeloperoxidase evaluation. 
Oxidative stress
The thiobarbituric acid method was used to quantify 
lipid peroxidation in tissue by measuring thiobarbituric acid-
reactive substances (TBARS). The tissue was homogenized 
in 1.15% KCl buffer (100 mg/mL) and centrifuged at 
14,000 g for 20 min. The supernatant was then stored at 
-70°C. An aliquot of the supernatant was added to a reaction 
mixture of 1.5 mL 0.8% thiobarbituric acid, 200 µL 8.1% 
(v/v) solution (SDS), 1.5 mL 20% (v/v) acetic acid and 
600 µL distilled H2O. The new solution had a pH of 3.5 
and was heated to 90°C for 45 min. After cooling to room 
temperature, the samples underwent centrifugation at 10,000 
g for 10 min, and absorbance was measured at 532 nm 
using 1,1,3,3-tetramethoxypropane as an external standard. 
The quantity of lipid peroxide was reported as nmol of 
malondialdehyde (MDA) equivalents/mg protein.30
Mitochondrial oxygraphic measurement
Liver tissue was prepared as previously described. 
Mitochondrial oxygen consumption was measured 
polarographically using a Gilson 5/6 H Oxygraph (Gilson 
Medical Electronics, Inc., Middleton, WI, USA) at 28°C. 
Respiration states 3 and 4 were defined and calculated 
according to the method of Chance31 as ADP-stimulated 
and ADP-limited respiration, respectively. The respiratory 
control index (RCI) was measured and represented the ratio 
of state 3 to state 4 (S3/S4). Respiration states S3 and S4 were 
measured and reported as ng atoms of O2 min-1 mg protein-1. 
Mitochondrial protein content was determined using the 
method of Lowry et al.32 The ratio of ADP added to oxygen 
consumed was calculated and recorded as the ADP/O ratio. 
The RCI and ADP/O ratio served as indices of oxidative and 
phosphorylative mitochondrial function, respectively.
Histology
Both ischemic and non-ischemic parts of the liver were 
harvested for histological examination. Liver tissue was 
fixed in 10% formalin solution, processed, and stained with 
hematoxylin-eosin and Masson Trichrome. The following 
histological variables were assessed and scored from 0 
to 3: macro- and microvacuolar fatty change, fatty zonal 
distribution, foci of necrosis, portal and perivenular fibrosis, 
the inflammatory infiltrate and its zonal distribution.
Statistical analysis
Results were expressed as the means ± standard error 
(SE) and were statistically analyzed using the Mann-
Whitney test and Fisher‘s exact test. p < 0.05 was considered 
statistically significant. 
RESULTS
In general, all experimental groups (I, II, III and IV) 
showed a greater response than the SHAN group for all 
assessments measured (p<0.05).
Experimental model of steatosis 
Microscopically, the degree of steatosis in rats that 
received the protein-free diet (Figure 2a) was significantly 
greater than in rats that received the balanced diet (Figure 2b). 
Figures 2 - Representative histological sample of a liver from a control 
animal showing normal features (A) compared to a liver from an animal 
with a protein-free diet and severe steatosis (B) (HE 200x).
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The animals on the protein-free diet developed malnutrition 
and lost approximately 30% of their body weight after 21 
days. 
Liver mitochondrial oxygraphic measurement
The RCI indicates oxidative phosphorylation activity. In 
the non-steatotic condition, the RCI revealed no difference 
between the control and SNAC groups. The ADP/O ratio 
indicates the level of coupling between the phosphorylation 
activity and the mitochondrial respiration. In the non-
steatotic groups, there was no significant difference 
between the control and SNAC groups. However, in 
steatotic groups, SNAC treatment resulted in an improved 
ADP/O ratio in the liver ischemic samples (p=0.01) 
(Figure 3).
Liver oxidative stress
Treatment with SNAC appeared to result in decreased 
liver oxidative stress. Groups treated with SNAC showed 
no difference in lipid peroxidation as determined by the 
thiobarbituric acid method (MDA) compared to controls 
(p=0.07). The oxidative stress was significantly higher in 
the steatotic groups than in the non-steatotic groups (p<0.01) 
(Figure 4). 
Liver histology
In the non-steatotic condition, all histological 
parameters were similar between the SNAC and control 
groups. Conversely, the steatotic groups showed less 
intraparenchymal hemorrhage in the ischemic liver (p=0.02) 
(Figures 5a, 5b and 6). Moreover, the steatotic group had 
Figure 3 - ADP/O ratio (ratio of ADP added to oxygen consumed) in ischemic 
livers of steatotic control group III and steatotic SNAC group IV; p=0.01.
Figure 4 - Lipid peroxidase activity in liver tissue, measured as thiobarbituric 
acid-reactive substances (TBARS) and reported as nmol of malondialdehyde 
(MDA) equivalent/mg protein, of control group I, SNAC group II, steatotic 
control group III and steatotic SNAC group IV; p=0.07.
Figures 5 - Representative histological sample of a steatotic, ischemic liver 
from a control animal with severe steatosis and hemorrhage (A) compared 
with a steatotic, ischemic liver from an animal treated with SNAC that shows 
moderate steatosis without hemorrhage (B) (HE 200x).
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higher levels of intraparenchymal hemorrhage than did the 
control group (p=0.02) (Figures 2a and 2b).
DISCUSSION
Steatosis is a risk factor for liver transplantation33 and 
liver resection, and it is associated with higher morbidity 
and mortality rates.9,34 Liver damage from steatosis is caused 
by hepatic mitochondrial impairment and oxidative stress.35 
In our study, higher levels of intraparenchymal hemorrhage 
and oxidative stress in the steatotic group confirmed the 
vulnerability and increased susceptibility of steatotic livers 
to IR injury (Figures 2a and 2b).
We analyzed the effects of an NO donor, SNAC, on 
IR injury in steatotic and non-steatotic livers. Endothelial 
dysfunction caused by IR injury may impair constitutive NO 
release37 and therefore reduce NO production in the early 
reperfusion period. SNAC decreases the oxidative stress in 
experimental models of steatosis and in skeletal muscle that 
undergoes IR injury.24-26 Therefore, S-nitrosothiol may be 
beneficial in cases of IR injury in steatotic livers. Our results 
also indicate that administration of SNAC after IR injury to 
steatotic livers can lead to improved mitochondrial function 
(Figures 3) and reduced oxidative stress (Figure 4).
Mitochondria are involved in fatty acid β oxidation and 
oxidative phosphorylation. Additionally, these organelles 
are an important source of reactive oxygen spieces 
(ROS). Impairment of their activity plays a central role in 
steatotic liver damage. SNAC may serve to decrease liver 
oxidative stress via two mechanisms. First, SNAC may 
improve mitochondrial function, thus leading to reduced 
ROS production. Second, SNAC may minimize damage 
to circulation in the liver, thus reducing hemorrhage in 
ischemic livers, as we observed in our study.
Hepatic microcirculation and oxidative stress are 
important factors related to IR injury. These factors are 
already present in steatotic livers and are aggravated in 
ischemic liver injury during reperfusion. An interesting 
finding from our study was that SNAC did not substantially 
alter the IR lesions in non-steatotic livers. Meanwhile, in 
steatotic livers that had severe lesions, administration of 
SNAC resulted in improvement of the IR lesions.
In this study, we confirmed that steatosis increases 
susceptibility to severe lesions after IR injury. Additionally, 
we demonstrated that SNAC can ameliorate the response 
of steatotic livers to IR and reduce intraparenchymal 
hemorrhage. Intraparenchymal hemorrhage is a histological 
lesion that demonstrates severe damage. Among the 
histological changes that we observed after IR injury, this 
type of lesion was significantly different between the treated 
and non-treated groups. 
Indeed, the present study confirmed greater IR injury 
in steatotic livers when compared to non–steatotic livers. 
Furthermore, hepatic IR lesions responded differently to 
treatment, regardless of whether steatosis was present.
Peroxynitrite is a highly reactive free radical formed 
by the combination of NO with a superoxide anion. Under 
normal conditions, this reaction is prevented by continuous 
removal of NO by hemoglobin.38 Nonetheless, during the 
later stages of reperfusion, NO production increases as a 
result of the expression of intrinsic nitric oxide synthase 
(iNOS). Excessive NO production leads to the formation 
of peroxynitrite, which causes hepatic injury.37,39 SNAC is 
an NO donor; therefore, a large quantity of this substance 
can itself produce peroxynitrite and nitrative stress. Thus, 
the timing of the administration of this drug is crucial 
to ameliorate IR injury in the liver and not cause further 
damage. In our study, we observed that administration of 
the NO donor SNAC led to a benefit in the final period of 
ischemia and in the early period of reperfusion.
In conclusion, this study confirms a poor outcome from 
IR injury in steatotic livers. Additionally, we show that 
SNAC effectively protects against IR injury in steatotic livers 
but not in normal livers. 
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